Opportunities And Pain Points For CGT Innovation And Market Access

After a difficult funding year for cell and gene therapies in 2023, optimism is the resounding sentiment among industry stakeholders at the start of the new year. Significant regulatory successes and a healthy pipeline of CGTs from pre-clinical to pre-registration stages pave the way for a promising 2024.

While there is much optimism, there remains caution over how best to address industry pain points in the evolving landscape. These considerations were reflected at Advanced Therapies Week 2024, with a discussion about initiatives to expand patient access to CGTs by overcoming logistic, regulatory strategy, and commercialization challenges being a central focus.

The conference – held in Miami from January 16 to 19 – brought together leaders from all sectors to discuss the various opportunities and pain points with cell and gene therapies across product development, regulatory hurdles, commercialization, and market and patient access.

This article captures some of the key insights colleagues across the industry shared during the event and analyzes what these mean in the broader context of successfully bringing CGTs to patients.